ArticleTranslational oncology2026
Statins targeting mevalonate-geranylgeranyl diphosphate pathway inhibit proliferation in NK/T lymphoma by promoting pyroptosis.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis in Lymphoproliferative Disorders.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyroptosis, an inflammation-driven programmed cell death, plays a pivotal role in the carcinogenicity of various tumors. Given the proven antitumor effects of statins, this study investigated whether statins suppress natural killer /T cell lymphoma (NKTCL) via pyroptosis and the underlying mechanism. NKYS and YT cells were treated with different concentrations of statins. The carcinogenicity of cells was validated through cell viability and invasion assays. The level of cell cycle, apoptosis, and the number of pyroptosis cells were evaluated via flow cytometry. Western-blot and immunofluorescence assays were conducted to verify the expressions of pyroptosis and immunity related proteins. The morphological characteristics of cell pyroptosis were observed via transmission electron microscopy. A subcutaneous transplant tumor model was used to verify the inhibitory effect of fluvastatin (FLU) on NKTCL cells in vivo. FLU inhibited the carcinogenicity of NKTCL cells in a concentration-dependent manner, and activated pyroptosis and its related immunity levels, which were represented by swelling of cell morphology, formation of inflammasome, and elevated expressions of gasdermin D, cleaved caspase-1 and interleukin-1β/18. Administration of pyroptosis inhibitors and exogenous mevalonate (MVA) or geranyl pyrophosphate (GGPP) partially weakened the inhibitory effect of FLU on NKTCL cells both in vitro and in vivo. Lastly, FLU and gemcitabine demonstrated satisfactory synergistic effects in tumor suppression and pyroptosis activation. Our data suggest that FLU represses NKTCL growth by promoting pyroptosis via the MVA-GGPP pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.